Merck Offering Refunds for 340B Overcharges

Merck is providing refunds to 340B covered entities for purchases of 17 products during the third quarter of 2020.

Drug manufacturer Merck is providing 340B covered entities with refunds for overcharges on 17 NDCs for purchases between Jan. 1 and March 31, 2019, the company says in a new public notice on the U.S. Health Resources and Services

Read More »

California Asks Judge to Dismiss 340B Health Centers’ Suit Challenging Medicaid Drug Payment Change

California says its consolidation of Medicaid prescription drug services under Medicaid fee for service (Medi-Cal Rx) does not deprive 340B health centers of revenue to which they are entitled.

California’s consolidation on Jan. 1 of all its Medicaid (Medi-Cal) prescription drug services under Medi-Cal fee for service does not violate federal law and does not deprive the state’s 340B health centers “of any reimbursement or revenue to which they

Read More »

Signify Health Acquires Caravan Health For $250 Million

Signify Health has signed an agreement to acquire Caravan Health, a company that helps hospitals and health systems that have value-based care arrangements. These services include maximizing 340B savings.

Signify Health, a value-based healthcare platform with a network of over 3,000 physician practices and facilities, has signed an agreement to acquire Caravan Health, a company that helps hospitals and health systems with value-based care arrangements maximize 340B savings, the

Read More »

340B INDUSTRY LEADER SPOTLIGHT

Robert Ferraro, Chief Pharmacy Officer, Ravin Consultants

Robert Ferraro headshot
Robert Ferraro

Q: Where did you grow up?

I grew up in North Providence, Rhode Island. I moved to Sarasota, Florida after graduating pharmacy school.

Q: Where did you go to college/graduate school?

I received my Doctor of Pharmacy degree from the University of Rhode Island. After working in various clinical and administrative positions, I discovered my passion

Read More »

Breaking News

Federal Judge Vacates HRSA’s Finding that AstraZeneca’s 340B Contract Pharmacy Policy Is Illegal

A federal district judge today struck down and vacated HRSA's May 2021 finding that AstraZeneca's 340B contract pharmacy policy violates the 340B statute.

A federal district judge in Wilmington, Del., today struck down and vacated the federal government’s finding that drug maker AstraZeneca’s conditions on 340B pricing when covered entities use contract pharmacies violates the 340B statute.

U.S. District Judge Leonard Stark of

Read More »

HHS Secretary Becerra Pledges to Keep Fighting Against 340B Contract Pharmacy Restrictions “Because it’s the Law”

HHS Secretary Xavier Becerra told health centers yesterday that “we’re going to continue to fight” drug manufacturers that restrict 340B pricing when covered entities use contract pharmacies “because it’s the law.”

U.S. Health and Human Services (HHS) Secretary Xavier Becerra said yesterday that “we’re going to continue to fight” drug manufacturers that restrict 340B pricing when covered entities use contract pharmacies “because it’s the law.”

Becerra’s Feb. 14 remarks about manufacturers’

Read More »

In a Win for Health Centers, 340B ADR Panel Says Proceedings Against AstraZeneca & Sanofi Must Go On

A 340B administrative dispute resolution (ADR) panel said it will not stop proceedings in the National Association of Community Health Centers’ complaint against AstraZeneca and Sanofi.

A 340B administrative dispute resolution (ADR) panel decided late last week that it will not stop proceedings in the National Association of Community Health Centers’ (NACHC) dispute-resolution petition over drug manufacturers AstraZeneca and Sanofi’s conditions on 340B pricing when covered

Read More »

In a Move that May Get Significant Pushback, Lilly Signals that it Can Recoup 340B Underpayments from Entities at its Discretion

Eli Lilly signaled late last week that it thinks it can seek more for its products from 340B covered entities if it learns later that it charged them less than what the company perceives the law allows.

Drug manufacturer Lilly indicated late last week that it reserves the right to seek additional compensation for its products from 340B covered entities if it learns later that it charged them less than what the company perceives the 340B statute

Read More »

Hospital Groups Pan GSK’s New 340B Contract Pharmacy Policy, PhRMA Says It Will Continue to Push for Reform

Hospital groups are criticizing GlaxoSmithKline's new 340B contract pharmacy policy. PhRMA says it will keep pushing to change 340B.

America’s Essential Hospitals and 340B Health yesterday denounced GlaxoSmithKline’s (GSK) new restrictions on 340B pricing when hospitals use contract pharmacies. Pharmaceutical Research and Manufacturers of America (PhRMA) said this morning it will keep pushing for “much needed changes” to

Read More »

News Alert: GlaxoSmithKline Becomes the 14th Drug Maker to Limit 340B Contract Pharmacies

GlaxoSmithKline today announced a new 340B contract pharmacy policy that affects nine of its inhaled medicines and applies to hospitals only.

UPDATE Monday, Feb. 14, 2022, 1:30 p.m. EST—The U.S. Health Resources and Services Administration (HRSA) said, “We are reviewing GSK’s policy and will evaluate next steps as needed.”

Drug manufacturer GlaxoSmithKline (GSK) told 340B covered entities this morning that effective

Read More »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
×
×

*Sign up for news summaries and alerts from 340B Report

Site Footer Live